Publications by authors named "Peter Gilbar"

Claim this Profile
P
Preventing drug vial wastage and reducing expenditure associated with injectable cancer drugs: International oncology pharmacy survey.
Peter J Gilbar, Carole R Chambers, Felice Musicco

J Oncol Pharm Pract· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab.
Aarya Murali, Philip Wong, Peter J Gilbar, Hilda M Mangos

J Oncol Pharm Pract· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of mortality within 30 days of systemic anticancer therapy and comparison with a previous audit at an Australian Regional Cancer Centre.
Bernadatte Zimbwa, Peter J Gilbar, Mark R Davis, Srinivas Kondalsamy-Chennakesavan

J Oncol Pharm Pract· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab.
Peter J Gilbar, Marcus Sr Dickey

J Oncol Pharm Pract· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature.
Nicole R Pringle, Peter J Gilbar, Guranjan D Grewal

J Oncol Pharm Pract· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe cisplatin-induced renal toxicity in a patient with xeroderma pigmentosum.
Peter J Gilbar, Khageshwor Pokharel

J Oncol Pharm Pract· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
Hannah Van Belle, Sara A Hurvitz, Peter J Gilbar, Hans Wildiers

Breast Cancer Res Treat· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Peter J Gilbar, Khageshwor Pokharel, Hilda M Mangos

J Oncol Pharm Pract· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vincristine must NEVER be prepared or administered in a syringe.
Peter Jeffrey Gilbar

Leuk Lymphoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The continuing importance of oncology case reports.
Peter J Gilbar, Barry R Goldspiel

J Oncol Pharm Pract· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure.
Peter J Gilbar, Mark R Davis

J Oncol Pharm Pract· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab-induced thrombotic thrombocytopenic purpura.
Marcus Sr Dickey, Anant J Raina, Peter J Gilbar, Brendan L Wisniowski, Joel T Collins

J Oncol Pharm Pract· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated beta human chorionic gonadotropin in a non-pregnant female diagnosed with anal squamous cell carcinoma.
Khageshwor Pokharel, Peter J Gilbar, Scott K Mansfield, Lekshmi M Nair, Albertina So

J Oncol Pharm Pract· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inadvertent intrathecal administration of vincristine: Time to finally abolish the syringe.
Peter J Gilbar

J Oncol Pharm Pract· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature.
Anant J Raina, Peter J Gilbar, Guranjan D Grewal, David J Holcombe

J Oncol Pharm Pract· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic anticancer therapy in the last 30 days of life: Retrospective audit from an Australian Regional Cancer Centre.
Peter J Gilbar, Ian McPherson, Genevieve G Aisthorpe, Srinivas Kondalsamy-Chennakes

J Oncol Pharm Pract· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How can the use of closed system transfer devices to facilitate sharing of drug vials be optimised to achieve maximum cost savings?
Peter J Gilbar, Carole R Chambers, Johan Vandenbrouche, Paul Jm Sessink, Timothy G Tyler

J Oncol Pharm Pract· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status of drug vial optimization use to prevent waste associated with injectable anticancer agents.
Shinya Suzuki, Peter Gilbar, Bo Yu, Chihiro Matsuyama, Masakazu Yamaguchi

J Oncol Pharm Pract· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shared decision making can aid the informed consent process for end-of-life chemotherapy in cancer patients.
Peter Gilbar

J Oncol Pharm Pract· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How can we ensure value for money from expenditure on injectable cancer drugs?
Peter J Gilbar, Carole R Chambers

J Oncol Pharm Pract· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A Survey to Compare the Specifications and Stability of Anticancer Drugs in Japan, the United States, Canada, and Australia].
Chihiro Matsuyama, Shinya Suzuki, Peter J Gilbar, Masakazu Yamaguchi

Gan To Kagaku Ryoho· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A further strategy to combat the high price of anticancer drugs.
Peter J Gilbar

Nat Rev Clin Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities to significantly reduce expenditure associated with cancer drugs.
Peter J Gilbar, Carole R Chambers, Erin C Gilbar

Future Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient.
Peter J Gilbar, Howard Mutsando, Joshua P Richmond, Ronald B Middleton

Int J Hematol Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The drug industry can help reduce cancer drug costs.
Peter J Gilbar, Margot J Tannock

BMJ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis